Skip to main content
Publications
Tam S, Neslund-Dudas C, Barrett AM , Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis . Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J , Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A, SISAQOL-IMI Consortium. Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines nitiative (SISAQOL-IMI): stakeholder views, objectives, and procedures . Lancet Oncol. 2023 Jun;24(6):e270-83. doi: 10.1016/S1470-2045(23)00157-2
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J , Bennett L , Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma . Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L , Wang J , Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study . Lancet Oncol. 2022 Jun;23(6):768-80. doi: 10.1016/S1470-2045(22)00212-1
Ribera A, Gimenez E, Oristrell G, Osorio D, Marsal JR , Garcia-Perez L, Ballesteros M, Rodenas E, Belahnech Y, Escalona R, Rivas N, Roca-Luque I, Ferreira-Gonzalez I, Espallargues M. Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death . Rev Esp Cardiol (Engl Ed). 2022 Jan;75(1):12-21. doi: 10.1016/j.rec.2021.05.004
Galian-Gay L, Gordon B, Marsal JR , Rafecas A, Pijuan Domenech A, Castro MA, Subirana Domenech MT, Sureda C, Miranda B, Marti G, Garcia-Dorado D, Dos Subira L. Determinants of long-term outcome of repaired pulmonary valve stenosis . Rev Esp Cardiol (Engl Ed). 2020 Feb;73(2):131-8.
Garcia-Albeniz X , Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02) . Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J , Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. Individual trade‐offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma . Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257
Allhusen V, Belsky J, Kersey HB, Booth C, Bradley R, Brownell CA, Burchinal M, Caldwell B, Campbell SB, Clarke-Stewart KA, Cox M, Friedman SL, Hirsh-Pasek K, Houts R, Huston A, Jaeger E, Kelly JF, Knoke B, Kochanoff A, Marshall N, McCartney K, McLeod L , Morrison FJ, O'Brien M, Owen MT, Payne C, Phillips D, Pianta R, Robeson WW, Spieker S, Vandell DL, Wallner-Allen KE. Do children's attention processes mediate the link between family predictors and school readiness? Dev Psychol. 2003 Jan 1;39(3):581-93.